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Abstract
This review considers the role of intracellular bacteria in adverse pregnancy outcomes, such as miscarriage, stillbirths, and preterm
labour. The cause of miscarriage, stillbirth and preterm labour often remains unexplained. Intracellular bacteria that grow either poorly
or not at all on media used routinely to detect human pathogens could be the aetiological agents of these obstetric conditions. For exam-
ple, Listeria monocytogenes and Coxiella burnetti are intracellular bacteria that have a predilection for the fetomaternal unit and may induce
fatal disease in the mother and/or fetus. Both are important foodborne or zoonotic pathogens in pregnancy. Preventive measures, diag-
nostic tools and treatment will be reviewed. Moreover, we will also address the importance in adverse pregnancy outcomes of other
intracellular bacteria, including Brucella abortus and various members of the order Chlamydiales. Indeed, there is growing evidence that
Chlamydia trachomatis, Chlamydia abortus and Chlamydia pneumoniae infections may also result in adverse pregnancy outcomes in humans
and/or animals. Moreover, newly discovered Chlamydia-like organisms have recently emerged as new pathogens of both animals and
humans. For example, Waddlia chondrophila, a Chlamydia-related bacterium isolated from aborted bovine fetuses, has also been implicated
in human miscarriages. Future research should help us to better understand the pathophysiology of adverse pregnancy outcomes caused
by intracellular bacteria and to determine the precise mode of transmission of newly identiﬁed bacteria, such as Waddlia and Parachlamy-
dia. These emerging pathogens may represent the tip of the iceberg of a large number of as yet unknown intracellular pathogenic agents.
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Introduction
There is accumulating epidemiological and experimental evi-
dence that maternal infection is a signiﬁcant risk factor for
adverse pregnancy outcomes. Untreated infection may cause
miscarriage, stillbirth and preterm labour by several mecha-
nisms, including direct fetal infection, placental damage, and
severe maternal illness. In many instances, however, no
pathogens are identiﬁed, despite increases in the levels of
inﬂammatory markers in the mother or histological evidence
of chorioamnionitis. Intracellular bacteria, which do not grow
on media that are used routinely to detect human pathogens
from clinical samples, could be the aetiological agents of
these obstetric complications.
The effects of several human infections with intracellular
bacteria on the outcome of pregnancy have been recognized
for many years. Indeed, Listeria monocytogenes, Coxiella burnetti
and Chlamydia species are known agents of adverse preg-
nancy outcomes. However, owing to their fastidious growth
requirements, their role probably remains largely underesti-
mated. With the increased availability of modern diagnostics
and rigorous screening, a higher proportion of agents may
now be detected during pregnancy. Moreover, much of what
is known about the pathogenesis of these intracellular micro-
organisms has emerged within the past few years as a result
of improved molecular-based tools being available for their
detection.
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We will ﬁrst describe well-known intracellular infections
during pregnancy, such as those caused by L. monocytogenes,
C. burnetti and Chlamydia species, and then summarize cur-
rent knowledge on the role of Chlamydia-like pathogens dur-
ing pregnancy. This review will focus on the epidemiology,
pathogenesis, zoonotic potential and mode of transmission of
all of these intracellular bacteria (Table 1).
Listeria
L. monocytogenes is a small, facultative, intracellular, Gram-
positive bacterium. The bacterium is particularly successful in
causing foodborne diseases, because it can continue to
slowly multiply even in properly refrigerated foods. Listeria
infects many types of animal, especially ruminants, and is thus
an important cause of zoonoses. However, soil, vegetables
and milk may also be contaminated. In recent years, an
increasing rate of listeriosis has been reported [1,2].
Whereas much has now been learned about outbreaks of lis-
teriosis, sporadic listeriosis still represents the majority of
cases.
The rate of infection is highest among neonates, adults
>60 years of age, immunocompromised patients and preg-
nant women. Pregnant women account for 27% of all cases,
and 60% of cases occur among 10–40-year-olds. Moreover,
pregnant women have a 20-fold increased risk of developing
diseases as compared with the general population [3,4], indi-
cating that pregnancy may constitute a risk factor for the
acquisition of listeriosis. In contrast to the other groups at
risk cited above, pregnant women rarely present with gastro-
enteritis or meningitis. However, more than 30% of infec-
tions during pregnancy result in miscarriage, stillbirth or
premature labour [5]. Most maternal infections occur follow-
ing ingestion of the organism in food during the third trimes-
ter of pregnancy, when maternal T-cell immunity is most
impaired [4]. Alkalinization of the stomach by antacids or
iron supplements [6], which are frequently prescribed during
pregnancy, promotes infection. Listeria crosses the mucosal
barrier of the intestine to disseminate haematogenously to
any site, with a unique tendency to infect the fetoplacental
unit. Bacteraemia generally manifests clinically as non-speciﬁc
inﬂuenza-like symptoms, and may remain asymptomatic. The
fetus may be stillborn or die within hours of a disseminated
form of listerial infection known as granulomatosis infantisep-
tica, which is characterized by the widespread presence of
microabscesses and granulomas. The highest concentrations
of bacteria are found in the lung and gut, suggesting that
infection is acquired in utero via inhalation of infected amni-
otic ﬂuid.T
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Smith et al. [5] recently reviewed 36 cases of maternofetal
listeriosis. The mothers were generally only mildly affected by
the infection. Twelve pregnancies ended with abortion or still-
birth. Among the 24 children born alive, 15 were diagnosed
with bacteraemia/septicaemia, three with pneumonia, and
three with neonatal meningitis; three were unaffected. Only
one of the live-born children died from the infection, and none
of the surviving children showed signs of permanent damage.
In another study [7], 16.7% of all cases of listeriosis reported
in the USA were pregnancy-related. Among 128 cases of ma-
ternofetal infection, four resulted in neonatal deaths and 26
(20.3%) in fetal loss. Invasive illnesses in newborns (n = 85)
were mainly meningitis (32.9%) and sepsis (36.5%). Pregnant
women with Listeria infection were more likely to belong to
ethnic minorities, as reported by others [2].
Listeriosis may be diagnosed by culture of Listeria from
maternal blood, amniotic ﬂuid, placenta, meconium, or lochia,
as well as from tracheal aspirates or ear swabs from newborns
[4]. When bacteria are obtained in culture, bacterial identiﬁca-
tion at the species level may be performed with the use of a
few different phenotypic analyses, which include Gram staining,
catalase, motility, haemolysis, and the Christie, Atkins and
Munch-Petersen (CAMP) reaction test (Fig. 1). Matrix-assisted
laser desorption ionization time-of-ﬂight mass spectrometry
may also provide rapid and accurate identiﬁcation. Identiﬁca-
tion at the species level is especially important when a member
of the genus Listeria is isolated from a possible source of an
outbreak, as the other, non-pathogenic, species may also con-
taminate the food. PCR is useful when antibiotic treatment has
already been started in cases of preterm labour, as prior antib-
iotherapy may compromise culture. Since listeriosis during
pregnancy may be fatal, blood cultures should be considered
for any pregnant woman presenting with fever, inﬂuenza-like
illness, or gastrointestinal symptoms [8]. As asymptomatic fae-
cal carriers have been reported, vaginal or stool cultures are
not recommended. Antimicrobial treatment started before a
deﬁnite diagnosis has been made can result in the birth of a
healthy infant. Thus, any fever during pregnancy in someone
with a positive history of consumption of raw vegetables,
uncooked meat or non-pasteurized milk raises suspicion of Lis-
teria infection, and should be empirically treated with intrave-
nous ampicillin (200 mg/kg/day, which corresponds to 12 g/
day, i.e. 2 g every 4 h) for 2–3 weeks [4,9]. For women with
proven b-lactam allergy, erythromycin may be considered,
(a) (b)
(c) (d)
FIG. 1. Phenotypic identiﬁcation of Listeria at the species level. Listeria spp. appear as short Gram-positive rods (a). Listeria monocytogenes is b-
haemolytic (b); this haemolysis allows discrimination of L. monocytogenes from Listeria innocua (the most common non-pathogenic Listeria species),
which is non-haemolytic (c); to differentiate L. monocytogenes from Listeria seelgeri and Listeria ivanovii, which are haemolytic, the Christie, Atkins
and Munch-Petersen (CAMP) test is generally used (c); brieﬂy, the haemolysis caused by L. monocytogenes is enhanced in the presence of Staphylo-
coccus aureus, whereas the haemolysis caused by L. ivanovii is increased by the presence of Rhodococcus equii. Note that, in contrast to Lactobacillus
spp., Listeria species are catalase-positive and motile; the test of motility is shown in (d).
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despite its poor transplacental passage leading to subtherapeu-
tic concentrations in both the fetal serum and amniotic cavity
[1]. Concerning prevention, pregnant women should be
advised to avoid consumption of raw milk, unpasteurized soft
cheeses, uncooked meats, refrigerated pate´s, and smoked sea-
food [4].
Coxiella
Increased awareness and better diagnostic tests may not be
sufﬁcient to explain the rising number of recent outbreaks of
Q-fever [10–12]. Q-fever is a widespread zoonosis caused
by C. burnetii, an intracellular Gram-negative bacterium. In
cattle, sheep, and goats, C. burnetii infection is often asymp-
tomatic [13,14]. However, infection of pregnant animals is
associated with stillbirth and spontaneous abortion [14].
Infected placentas contaminate the soil at the time of par-
turition, leading to the persistence of viable organisms for
years [14,15]. Aerosols from infected placentas, secretions
or excretions of animals are the major source of transmis-
sion to humans, and can occur many kilometres from the
animals [14]. The most commonly identiﬁed sources of
human infection are farm animals. Pets, especially cats, also
represent an important vector of the disease in urban areas
[16]. Ingestion of unpasteurized milk products is also a
source of human infection by C. burnetii [17], which is of
concern given the growing interest in ‘bio’ alimentation.
Moreover, there is growing evidence regarding the role of
air-conditioning as a potential source of Q-fever [18]. Inter-
human transmission has also been described [19,20]. A case
of Q-fever occurring after contact with an infected pregnant
patient at the time of delivery has been published [21].
Psychiatric patients may also represent an important risk
group [22]. C. burnetii is highly infectious, as a single bacte-
rium may infect a human [13].
Human primary infection is asymptomatic in 50% of
cases. However, acute Q-fever may also present with an
inﬂuenza-like illness, hepatitis, or pneumonia, and rarely
endocarditis [14,15]. Fever spontaneously resolves after
10 days, but approximately 5% of infected patients will
develop chronic Q-fever months to years after the acute
illness [14,15]. Endocarditis and aortic infections represent
the main forms of chronic Q-fever, mainly in patients with
valve lesions, arterial aneurysms, or prostheses, or in those
who are immunocompromised [15]. Less common presen-
tations include osteoarticular infections, chronic hepatitis,
and lung infections [15].
The prevalence of acute Q-fever has been reported to
be 1/2000 people, but epidemiological studies have demon-
strated 10–36% seropositivity in blood donors [20]. In
women with uneventful pregnancies, a seroprevalence rate
of 6.5% has recently been reported [23]. The prevalence of
Q-fever during pregnancy might be as high as 0.19% [24],
which is a similar value to those for other better-studied
maternal infections, such as those with cytomegalovirus
[25] and hepatitis C virus [26]. However, the incidence of
Q-fever during pregnancy is likely to be underestimated,
and thus underinvestigated. Indeed, obstetricians’ knowledge
about Coxiella is poor [20], and acute Q-fever is signiﬁcantly
more asymptomatic in pregnant women than in the general
population [20]. However, Q-fever may result in severe
obstetric complications, including spontaneous abortion
(26%), intrauterine growth retardation (5.3%) or fetal death
(5.3%), and premature delivery (44.7%) [20]. No teratoge-
nicity has been observed, although the ﬁrst trimester of
pregnancy is the period when there is the highest risk of
adverse pregnancy outcomes and chronic Q-fever for the
mother [20,27]. Coxiella represents a risk not only for the
pregnancy in which the infection occurs, but also for future
pregnancies. Seropositive women were found to be three
times more likely to have a current or previous neonatal
death [28]. In addition, pregnant women have been shown
to exhibit a ten-fold increased risk of chronic Q-fever rela-
tive to the general population (52.8% vs. 5%) [20,27].
Moreover, endocarditis may occur even in the absence of
underlying valvular lesions.
The pathophysiology of Coxiella in pregnancy remains
uncertain. Coxiella will colonize and multiply in the uterus and
placenta. Recent studies have shown that C. burnetii replicates
not only within human monocytes and macrophages, but also
within trophoblastic cells [29]. This may result in placental
insufﬁciency following vasculitis and vascular thrombosis.
Moreover, Coxiella has also been identiﬁed in fetal organs,
demonstrating possible transplacental transmission [20].
The diagnosis of acute Q-fever relies on the detection
of speciﬁc IgG and IgM antibodies directed to phase II
C. burnetii, whereas chronic Q-fever is indicated by high
titres of phase I IgG antibodies [14,20]. Immunoﬂuores-
cence is considered to be the reference standard for
Coxiella diagnosis [14,15,20]. However, serology can also
be performed by ELISA or the complement ﬁxation test
[14,30]. Infected tissues (placenta, heart valves, etc.) may
also be tested by PCR [14,20].
The treatment of choice for C. burnetti, doxycycline, is
contraindicated during pregnancy. In a series of 53 infected
pregnant patients, co-trimoxazole decreased the incidence of
the adverse pregnancy outcomes cited above, although it
was not curative in ten of 17 patients [27]. However, C. bur-
netii can be deﬁnitely treated with doxycycline after delivery.
CMI Baud and Greub Intracellular bacteria and adverse pregnancy outcomes 1315
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1312–1322
Other authors have reported successful treatment (unevent-
ful pregnancies) with azithromycin [31] or erythromycin and
rifampicin [32].
Brucella
Human brucellosis remains the most common zoonotic dis-
ease worldwide, with more than 500 000 new cases annually
[33,34]. Although brucellosis has been eradicated in many
developed countries, it is still endemic in the Mediterranean
area, Middle East, Southwest Asia, and parts of Latin Amer-
ica. In a recent study in the UK [23], only two of 438 preg-
nant women exhibited anti-Brucella antibodies, both patients
originating from Sudan.
Brucella species are intracellular bacteria that may infect
humans [34,35]. Four species may cause disease in
humans—Brucella abortus, Brucella melitensis, Brucella suis, and
Brucella canis—with the animal reservoirs being cattle, sheep
and goats, pigs, and dogs, respectively [34–37]. Two novel
species, Brucella ceti and Brucella pinnipedialis, have been iso-
lated from marine mammals [33,36].
In animals, brucellosis manifests as a chronic infection
resulting in abortion and sterility. A large bacterial load is
present in milk, urine, and the products of pregnancy
[33,37]. Intrauterine transmission, transmission during deliv-
ery and transmission through breast milk are among the
main routes of transmission in the mammalian reservoirs
[33,34].
Brucella infects humans via aerosol inhalation, ingestion, or
mucosal or skin abrasions. Suspicion of patient infection is
raised when a detailed history reveals ingestion of contami-
nated dairy products or when contact with infected animals
has occurred [33,34]. Recent reports also suggest possible
infection via blood transfusion and sexual transmission, and
from patients to medical personnel, especially in an obstetric
setting [38].
In humans, brucellosis is a multisystemic disease. Fever is
the most common feature, followed by osteoarticular
involvement (sacroiliitis, spondylitis, peripheral arthritis, and
osteomyelitis) [33–35,39]. However, all systems might be
affected, such as the nervous (neuropathies, chorea, and
meningoencephalitis), gastrointestinal, hepatobiliary (hepato-
megaly), genitourinary (orchiepididymitis, glomerulonephritis,
and renal abscesses), musculoskeletal, cardiovascular (endo-
carditis, mainly with involvement of the aortic valve) and pul-
monary (pleural effusions and pneumonia) systems.
Approximately 10% of patients with brucellosis experience
relapses, 90% of which occur within a year after discontinua-
tion of antimicrobial drug therapy [34]. Disease reactivation
has been described as long as 28 years after the initial infec-
tion [40].
Increased rates of spontaneous abortion, premature
delivery and intrauterine infection with fetal death have
been described among pregnant women with clinical evi-
dence of brucellosis [41,42]. Left untreated, surviving preg-
nancies may lead to serious sequelae for the newborn,
such as Brucella myocarditis [43], severe respiratory dis-
tress, and hepatosplenomegaly [44]. Women who received
early diagnosis and adequate treatment had successful
maternal and fetal outcomes [41]. Rifampicin 900 mg once
daily for at least 6 weeks is considered to be the regimen
of choice during pregnancy [37]. Tetracyclines (especially
doxycycline 100 mg twice daily for 6 weeks), the most
effective drugs for brucellosis, can only be initiated after
delivery [37]. Although vaccines are available for animals,
there is currently no licensed vaccine for brucellosis in
humans [33,36].
Brucellosis is routinely misdiagnosed, or at best diagnosed
incidentally; therefore, physicians in both endemic and non-
endemic areas should be aware of brucellosis and consider
this disease in the differential diagnosis of febrile episodes
during pregnancy. Blood culture is the reference standard
for the diagnosis of Brucella infection in humans [33,34]. The
Rose Bengal test is used as a screening serological test, and
positive results are conﬁrmed by the serum agglutination test
[45]. Other tests, such as ELISA and PCR, are increasingly
used for the diagnosis of brucellosis.
Chlamydia
Chlamydiae are obligate intracellular bacterial pathogens.
There is increasing evidence that Chlamydia trachomatis, Chla-
mydia pneumoniae and Chlamydia abortus infections may result
in adverse pregnancy outcomes in humans and/or animals [46].
Chlamydia trachomatis infection is the most commonly diag-
nosed bacterial sexually transmitted infection worldwide
[46,47] and a major cause of infertility [48,49]. Given the
importance of Chlamydia trachomatis in miscarriage and pre-
mature delivery, Chlamydia screening should be considered
as part of routine antenatal care [50]. This screening was
well accepted among young pregnant women, who recog-
nized the beneﬁt of screening and strongly supported its
implementation [50].
During the ﬁrst trimester, many studies (reviewed in [46])
have shown a relationship between miscarriage and Chla-
mydia trachomatis infection by detection of anti-chlamydial
IgG and/or IgA antibodies [51–55] and endocervical swabs
[55,56]. In a recent study performed in our university
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hospital, 386 women with and without miscarriage were pro-
spectively included [57]. Most patients suffered from a ﬁrst-
trimester miscarriage. The anti-Chlamydia trachomatis IgG
prevalence was higher in the miscarriage group (15.2%) than
in controls (7.3%, p 0.018). The association between Chla-
mydia trachomatis-positive serology and miscarriage remained
signiﬁcant after adjustment for age, origin, education level,
and number of sexual partners (OR 2.3, 95% CI 1.1–4.9).
Chlamydia trachomatis DNA was more frequently ampliﬁed
from products of conception or placentas taken from
women who had suffered miscarriages (4%) than from con-
trols (0.7%, p 0.026). Moreover, immunohistochemistry con-
ﬁrmed the presence of Chlamydia trachomatis in the placentas
of ﬁve of seven patients with positive PCR ﬁndings, whereas
immunohistochemistry gave negative ﬁndings in placentas
taken from all eight negative controls tested [57].
In the second and third trimesters, several studies have
suggested an association between molecular and/or serologi-
cal evidence of Chlamydia trachomatis infection in the mother
and premature uterine activity, premature birth of infants
with extremely low birthweight, and perinatal death [58–60].
Other studies have identiﬁed similar correlations between
preterm labour, premature preterm rupture of membrane
(PPROM), or prematurity and infection with Chlamydia tra-
chomatis [61–64].
The pathogenesis is still only partially understood. Chla-
mydial infection may increase the probability of an adverse
pregnancy outcome by infecting the fetus, by stimulating a
fetal inﬂammatory response, or by leading to excessive
maternal immunogenic reaction to its fetal heat shock pro-
tein-60 antigen [46,65].
In pregnant patients, Chlamydia trachomatis might be identi-
ﬁed from urine, as well as from vaginal, cervical or urethral
swabs. Nucleic acid ampliﬁcation offers high sensitivity
(>97%) and speciﬁcity (>99%), and is thus mostly used for
detection of Chlamydia trachomatis [47,66], largely replacing
cell culture and antigen-based detection methods (immuno-
logical assays).
The beneﬁt of widespread testing in terms of decreasing
the frequency of pregnancy complications has not been stud-
ied in randomized controlled intervention trials, for ethical
reasons. However, Chlamydia trachomatis testing should form
part of pre-conceptional screening, to reduce the prevalence
of adverse pregnancy outcomes [57]. Moreover, all women
experiencing a miscarriage should be screened for Chlamydia
trachomatis infection, and if found to be positive, should be
adequately treated to prevent recurrent episodes of miscar-
riage [46,57,67]. Finally, all patients presenting with preterm
uterine contractions and/or preterm premature rupture of
membranes should be tested for the presence of Chlamydia
trachomatis [46]. Azithromycin is safe during pregnancy, and
is the recommended treatment.
Chlamydia pneumoniae, a closely related intracellular bacte-
rium, which is known to cause respiratory tract infections
[68], has recently been associated with adverse pregnancy
outcomes, such as pre-eclampsia [69–73], intrauterine
growth restriction [74], and peripartum cardiomyopathy
[75]. A recent meta-analysis conﬁrmed an association
between anti-Chlamydia pneumoniae IgG seroprevalence and
the risk of developing pre-eclampsia [69]. This is most con-
sistent for women with a prior history of pre-eclampsia,
women who will develop early-onset pre-eclampsia, and
women with pre-eclampsia at the time of serological testing
[69].
Moreover, Xie et al. [69] showed that Chlamydia pneumo-
niae DNA copy numbers were signiﬁcantly higher in sera
from women with pre-eclampsia than in sera from normal
pregnant or non-pregnant controls. The physiopathology of
Chlamydia pneumoniae during pregnancy is unclear, but Chla-
mydia pneumoniae is able to infect human trophoblast cells
[70,74], Chlamydia pneumoniae DNA being more frequently
identiﬁed in the trophoblast cells of pre-eclamptic patients
than in controls [70]. Infection may reduce trophoblast inva-
sion into the uterine wall, which may lead to placental dys-
function and pre-eclampsia [70].
Chlamydia abortus (formerly Chlamydia psittaci sensu lato),
which causes fetal wastage in ruminants [76], is also aborti-
genic in many other species, such as swine, horses, rabbits,
guinea pigs, koalas, and mice [46]. In humans, Chlamydia abor-
tus has been implicated in spontaneous miscarriages or still-
births in farm women after contact with infected animals
[46,77–79]. The incubation period before miscarriage may
last for weeks or months after animal contact. Indeed,
human abortion generally occurs late in pregnancy and fol-
lowing a febrile inﬂuenza-like syndrome, with or without dis-
seminated intravascular coagulation or impaired liver and
renal function [46]. Women should therefore avoid contact
with ruminants during pregnancy [46].
Although other members of the family Chlamydiaceae
(Chlamydia pecorum, Chlamydia suis, and Chlamydia felis) have
also been associated with urogenital infection and adverse
pregnancy outcomes in many animals [80], no human zoo-
notic infection by these species has yet been described.
Chlamydia-like Organisms
In addition to the family Chlamydiaceae, new family-level
lineages have been added to the order Chlamydiales: Para-
chlamydiaceae, Simkaniaceae, Criblamydiaceae, Rhabdochlamydia-
CMI Baud and Greub Intracellular bacteria and adverse pregnancy outcomes 1317
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1312–1322
ceae, and Waddliaceae [80]. Members of these newly
described family-level lineages contain an 80–90% identical
16S rRNA-encoding gene sequence with members of the
Chlamydiaceae, and exhibit a Chlamydia-like replicative cycle.
Among these families, two species have been associated with
human adverse pregnancy outcomes, i.e. Parachlamydia
acanthamoebae and Waddlia chondrophila. Both species are
able to enter and replicate within human macrophages
before inducing a cytopathic effect [81,82]. Waddlia was also
recently shown to multiply inside endometrial cells [83]
(Fig. 2). These Chlamydia-like organisms are susceptible to
doxycycline and azithromycin, but resistant to b-lactams and
ﬂuoroquinolones [84,85].
Seroepidemiological and molecular studies provided the
ﬁrst evidence that P. acanthamoebae plays a role in human
pneumonia [68,86]. However, Parachlamydia might also be
an agent of miscarriage in humans. Indeed, in a study
including 438 women, none of the 169 uneventful pregnan-
cies had positive serological ﬁndings for Parachlamydia,
whereas seven (2.6%; p 0.047) of 269 women experiencing
a miscarriage exhibited Parachlamydia IgG titres of 1/64 or
greater [51]. Moreover, maternofetal transmission of
Parachlamydia has been recently described [87]: Parachlamy-
dia DNA was ampliﬁed by PCR from one of 78 amniotic
ﬂuid samples taken from patients who had spontaneous
premature deliveries (the patient, a 29-year-old woman, had
an amniocentesis at 16 weeks of gestation for a Down syn-
drome risk of 1/100; at that time, the patient had cough
and inﬂuenza-like symptoms; the pregnancy ended with a
premature spontaneous vaginal delivery 4 weeks before her
due date). Finally, 31% of respiratory samples from 29 pre-
mature babies hospitalized in neonatology units showed the
presence of Parachlamydia DNA [86]. Although neonatal
infections might have occurred after delivery, systemic
infection during pregnancy is possible and may have induced
the premature labour.
W. chondrophila, another Chlamydia-like organism, has also
been implicated in human adverse pregnancy outcomes [46].
A serological study showed a strong association between
miscarriage and the presence of anti-Waddlia antibodies [51].
The seroprevalence was higher in patients with sporadic
(31.9%) and recurrent (33%) miscarriage than in patients
with uneventful pregnancies (7.1%; p <0.001). Waddlia sero-
positivity was associated with animal contact (pets), suggest-
ing that this Chlamydia-like organism may be zoonotically
transmitted, but infection through contaminated water,
uncooked meat, milk or sexual contact might also be the
mode of transmission to humans. This strong serological
association was conﬁrmed in a second study (D. Baud, G.
Goy, M.-C. Osterheld, N. Borel, Y. Vial, P. Hohlfeld, A. Pos-
pischil, G. Greub, unpublished data). Moreover, a case was
identiﬁed that exhibited immunohistochemical and molecular
evidence of Waddlia infection [57].
The pathogenesis of adverse pregnancy events caused by
Parachlamydia and Waddlia remains to be deﬁned. The
recent availability of the Waddlia and Parachlamydia genomes
opened new research perspectives [88,89]. Because, in a
recent study, we observed the presence of Waddlia in
endometrial cells [57], we hypothethized that deciduitis
(a)
(b)
FIG. 2.Waddlia chondrophila within endometrial cells, as seen by
confocal microscopy. Note that, 48–72 h post-infection, there are
numerous bacteria (stained green with polyclonal anti-Waddlia anti-
bodies) in Ishikawa endometrial cells (a). However, at 96 h post-
infection, the bacteria transform into persistent enlarged aberrant
bodies that may be up to 5 lm in diameter (b). These persistent
forms may explain the occurrence of recurrent episodes of miscar-
riage.
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(infection of the maternal part of the placenta) may lead to
uterine contraction. However, at least in animals, abortion
may also occur following chorioamnionitis and fetal infec-
tion. Indeed, P. acanthamoebae was identiﬁed in aborted
bovine placenta samples [90–94], and W. chondrophila was
ﬁrst isolated from an aborted bovine fetus [95,96]. As
Waddlia was associated with recurrent miscarriage [46,51],
and may develop into aberrant bodies (a persistent stage;
see Fig. 2b), at least in vitro, upon infection of endometrial
cells [83], such persistence, if conﬁrmed in vivo, underlines
the likely importance of diagnotic procedures to identify
women with asymptomatic infection at risk of recurrent
miscarriage and who will clearly beneﬁt from therapy with
azithromycin or doxycycline.
Relationship Between Mammals and
Human Abortion
Cross-species infection is a major cause of emerging infec-
tious diseases [97], and has been promoted by intensive
animal husbandry, the presence of pets at home, and animal
migration [98]. The inﬂuence of human behaviour and envi-
ronmental perturbations induced by humans (deforestation
and climatic changes) is also responsible for newly emerging
human infections [99]. Few infectious diseases are human-
speciﬁc: most human pathogens also circulate in animals or
even originated in non-human hosts [97–100]. Indeed, these
pathogens have evolved elaborate mechanisms to jump
between species, such as domestic fowls, farm animals, and
humans [99]. Inﬂuenza, SARS, AIDS and Creutzfeldt–Jakob
disease are classic examples of zoonotic infections that are
transmitted from animals to humans [99,101].
Much attention has been focused on these pathogens,
which are of immediate global importance. Meanwhile, intra-
cellular bacteria have been neglected, as have crucial pro-
cesses such as cross-species transmission. However, several
emerging intracellular bacteria pose a serious and increasing
threat to human reproductive health, as pregnancy itself is
their target.
C. burnetti, B. abortus, Chlamydia abortus, W. chondrophila
and Parachlamydia are examples of intracellular bacteria
that induce both animal abortion and human miscarriage.
Either through direct contact with the host animals or
through ingestion of their products (meat and milk), the
same intracellular bacterium can induce a similar disease,
probably through the same pathophysiological pathway
[46]. It may be possible that many as yet unknown intra-
cellular bacteria are responsible for 50% of miscarriages of
unknown aetiology. The multi-host ecology of zoonoses
should lead to the development of effective control poli-
cies. Human disease surveillance must clearly be associated
with enhanced longitudinal veterinary and wild animal infec-
tion surveillance [101].
Recommendations and Guidelines for
Pregnant Women
Although primary preventive measures mainly concern veter-
inary practices, agricultural areas, pet shops, and the food
industry, every woman intending to become pregnant or
who is already pregnant should be informed about the fol-
lowing three main infection sources:
1 Environment: fruit and vegetables should be well washed
prior to consumption. Pregnant women should be
advised to avoid contact with soil, and ideally avoid gar-
dening. Work or contact with farm animals should be
discouraged, especially with pregnant or recently deliv-
ered animals. Pregnant women should not drink/eat non-
pasteurized milk or cheese.
2 Meat: handling of raw meat should be avoided. Only
well-cooked meat should be eaten. Raw food should not
be prepared at the same location and/or with the same
ustensils as those used to handle raw meat.
3 Domestic animals: domestic cats should be fed with
canned food rather than with raw meat. Contact with
pet’s faeces and cat litter should be strictly avoided.
Hands should be washed after contact with soil, dogs,
and cats, and before each meal.
Conclusions
C. burnetti has been associated with adverse pregnancy out-
comes. However, because of their intracellular lifestyle, the
detection of infections caused by these intracellular bacteria
is challenging. In the next decade, the number of reported
cases might increase as a result of improved tools for their
detection and better awareness of clinicians. C. burnetti and
Chlamydia species should be added to the TORCH screen in
the category of ‘Other etiological agents of intrauterine
causes of foetal mortality and morbidity’, which already
includes the following: viral hepatitis, syphilis, varicella and
herpes zoster. Women who are affected with any of the
TORCH pathogens during pregnancy are at risk for miscar-
riage, stillbirth, preterm labour, or delivering a child with
serious birth defects and/or illness. Thus, this test is per-
formed before pregnancy or as soon as pregnancy is diag-
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nosed to determine the mother’s history of exposure to
these organisms.
Concerning the different members of the order Chlamydi-
ales, and especially Chlamydia trachomatis, pre-conceptional
molecular testing should be offered to reduce the prevalence
of adverse pregnancy outcomes. When this is not possible,
this screening should be proposed during the ﬁrst antenatal
assessment (and following any adverse pregnancy outcomes).
In addition, there is increasing evidence of the human
pathogenicity of some Chlamydia-like organisms, especially as
agents of adverse pregnancy outcome. Consequently, there
is an urgent need for efﬁcient and standardized diagnostic
approaches, using both molecular and serological methods,
as well as immunohistochemistry protocols to conﬁrm the
presence of the bacteria in placental lesions or fetal tissues.
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